RSS Tenaya Reports Early Data From First Cohort Of Patients In MyPEAK-1 Trial Of TN-201

Currently reading:
 RSS Tenaya Reports Early Data From First Cohort Of Patients In MyPEAK-1 Trial Of TN-201

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,764
Likes
1,919
Credits
32,874©
Cash
0$
Tenaya Therapeutics (TNYA) has unveiled initial results from the MyPEAK-1 clinical trial's first cohort of patients undergoing TN-201 gene therapy. This therapy is being developed as a potential treatment for MYBPC3-associated hypertrophic cardiomyopathy, a condition stemming from inadequate levels of myosin-binding protein C. The company noted that the TN-201 data align with its expectations for this early phase of the study.

Preliminary findings from three patients in the initial dose cohort of 3E13 vg/kg indicate that TN-201 is generally well tolerated. Tenaya plans to continue monitoring these patients, with further data from the first cohort and the higher dosage second cohort expected by 2025.

On Tuesday, shares of Tenaya Therapeutics have fallen by 26% in pre-market trading.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips

Similar threads

Top Bottom